Research ExplorerPublicationsHeart Rate Reduction and Outcomes in Heart Failure Outpatien...

Heart Rate Reduction and Outcomes in Heart Failure Outpatients

Standard

Heart Rate Reduction and Outcomes in Heart Failure Outpatients. / Memenga, Felix; Rybczynski, Meike; Magnussen, Christina; Goßling, Alina; Kondziella, Christoph; Becher, Nina; Becher, Peter Moritz; Bernadyn, Julia; Berisha, Filip; Bremer, Wiebke; Sinning, Christoph; Blankenberg, Stefan; Kirchhof, Paulus; Knappe, Dorit.

In: J CLIN MED, Vol. 12, No. 21, 6779, 26.10.2023.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Memenga, F, Rybczynski, M, Magnussen, C, Goßling, A, Kondziella, C, Becher, N, Becher, PM, Bernadyn, J, Berisha, F, Bremer, W, Sinning, C, Blankenberg, S, Kirchhof, P & Knappe, D 2023, 'Heart Rate Reduction and Outcomes in Heart Failure Outpatients', J CLIN MED, vol. 12, no. 21, 6779. https://doi.org/10.3390/jcm12216779

APA

Memenga, F., Rybczynski, M., Magnussen, C., Goßling, A., Kondziella, C., Becher, N., Becher, P. M., Bernadyn, J., Berisha, F., Bremer, W., Sinning, C., Blankenberg, S., Kirchhof, P., & Knappe, D. (2023). Heart Rate Reduction and Outcomes in Heart Failure Outpatients. J CLIN MED, 12(21), [6779]. https://doi.org/10.3390/jcm12216779

Vancouver

Memenga F, Rybczynski M, Magnussen C, Goßling A, Kondziella C, Becher N et al. Heart Rate Reduction and Outcomes in Heart Failure Outpatients. J CLIN MED. 2023 Oct 26;12(21). 6779. https://doi.org/10.3390/jcm12216779

Bibtex

@article{7ed812298dec46f7acf71d4c9abe1cd5,
title = "Heart Rate Reduction and Outcomes in Heart Failure Outpatients",
abstract = "Aim. Pharmacologic reduction in heart rate with beta-blockers (BB) or ivabradine is associated with improved survival in heart failure (HF) with sinus rhythm. We analyzed the association of different heart rate-reducing drug treatments on outcomes in HF outpatients. Methods. Consecutive patients with HF in sinus rhythm referred to a specialized tertiary service were prospectively enrolled from August 2015 until March 2018. Clinical characteristics were assessed at baseline. We performed Cox regression analyses to examine the effect of the resting heart rate and different heart rate-reducing drug regimens on all-cause mortality and a composite endpoint of {"}all-cause mortality or heart transplantation{"} over a mean follow-up of 3.1 years. Results. Of the 278 patients included, 213 (76.6%) were male, the median age was 57.0 years (IQR 49.0-66.1), and 185 (73.7%) had an ejection fraction <40%. Most patients received BB in submaximal [n = 118] or maximum dose [n = 136]. Patients on BB in maximum dose plus ivabradine [n = 24] were younger (53.0 vs. 58.0 years) and had a lower EF (25 vs. 31%). Higher resting heart rate was associated with an increased risk of death or transplantation (HR 1.03 [1.01, 1.06], p = 0.0072), even after adjusting for age and sex. There were no differences between the groups concerning all-cause mortality or the composite endpoint. Conclusion. Our prospective study confirms the association between low heart rate and survival in HF patients receiving various heart rate-reducing medications. We could not identify a specific effect of either regimen.",
author = "Felix Memenga and Meike Rybczynski and Christina Magnussen and Alina Go{\ss}ling and Christoph Kondziella and Nina Becher and Becher, {Peter Moritz} and Julia Bernadyn and Filip Berisha and Wiebke Bremer and Christoph Sinning and Stefan Blankenberg and Paulus Kirchhof and Dorit Knappe",
year = "2023",
month = oct,
day = "26",
doi = "10.3390/jcm12216779",
language = "English",
volume = "12",
journal = "J CLIN MED",
issn = "2077-0383",
publisher = "MDPI AG",
number = "21",

}

RIS

TY - JOUR

T1 - Heart Rate Reduction and Outcomes in Heart Failure Outpatients

AU - Memenga, Felix

AU - Rybczynski, Meike

AU - Magnussen, Christina

AU - Goßling, Alina

AU - Kondziella, Christoph

AU - Becher, Nina

AU - Becher, Peter Moritz

AU - Bernadyn, Julia

AU - Berisha, Filip

AU - Bremer, Wiebke

AU - Sinning, Christoph

AU - Blankenberg, Stefan

AU - Kirchhof, Paulus

AU - Knappe, Dorit

PY - 2023/10/26

Y1 - 2023/10/26

N2 - Aim. Pharmacologic reduction in heart rate with beta-blockers (BB) or ivabradine is associated with improved survival in heart failure (HF) with sinus rhythm. We analyzed the association of different heart rate-reducing drug treatments on outcomes in HF outpatients. Methods. Consecutive patients with HF in sinus rhythm referred to a specialized tertiary service were prospectively enrolled from August 2015 until March 2018. Clinical characteristics were assessed at baseline. We performed Cox regression analyses to examine the effect of the resting heart rate and different heart rate-reducing drug regimens on all-cause mortality and a composite endpoint of "all-cause mortality or heart transplantation" over a mean follow-up of 3.1 years. Results. Of the 278 patients included, 213 (76.6%) were male, the median age was 57.0 years (IQR 49.0-66.1), and 185 (73.7%) had an ejection fraction <40%. Most patients received BB in submaximal [n = 118] or maximum dose [n = 136]. Patients on BB in maximum dose plus ivabradine [n = 24] were younger (53.0 vs. 58.0 years) and had a lower EF (25 vs. 31%). Higher resting heart rate was associated with an increased risk of death or transplantation (HR 1.03 [1.01, 1.06], p = 0.0072), even after adjusting for age and sex. There were no differences between the groups concerning all-cause mortality or the composite endpoint. Conclusion. Our prospective study confirms the association between low heart rate and survival in HF patients receiving various heart rate-reducing medications. We could not identify a specific effect of either regimen.

AB - Aim. Pharmacologic reduction in heart rate with beta-blockers (BB) or ivabradine is associated with improved survival in heart failure (HF) with sinus rhythm. We analyzed the association of different heart rate-reducing drug treatments on outcomes in HF outpatients. Methods. Consecutive patients with HF in sinus rhythm referred to a specialized tertiary service were prospectively enrolled from August 2015 until March 2018. Clinical characteristics were assessed at baseline. We performed Cox regression analyses to examine the effect of the resting heart rate and different heart rate-reducing drug regimens on all-cause mortality and a composite endpoint of "all-cause mortality or heart transplantation" over a mean follow-up of 3.1 years. Results. Of the 278 patients included, 213 (76.6%) were male, the median age was 57.0 years (IQR 49.0-66.1), and 185 (73.7%) had an ejection fraction <40%. Most patients received BB in submaximal [n = 118] or maximum dose [n = 136]. Patients on BB in maximum dose plus ivabradine [n = 24] were younger (53.0 vs. 58.0 years) and had a lower EF (25 vs. 31%). Higher resting heart rate was associated with an increased risk of death or transplantation (HR 1.03 [1.01, 1.06], p = 0.0072), even after adjusting for age and sex. There were no differences between the groups concerning all-cause mortality or the composite endpoint. Conclusion. Our prospective study confirms the association between low heart rate and survival in HF patients receiving various heart rate-reducing medications. We could not identify a specific effect of either regimen.

U2 - 10.3390/jcm12216779

DO - 10.3390/jcm12216779

M3 - SCORING: Journal article

C2 - 37959246

VL - 12

JO - J CLIN MED

JF - J CLIN MED

SN - 2077-0383

IS - 21

M1 - 6779

ER -